» Articles » PMID: 29325758

MiR-186-5p Upregulation Inhibits Proliferation, Metastasis and Epithelial-to-mesenchymal Transition of Colorectal Cancer Cell by Targeting ZEB1

Overview
Publisher Elsevier
Specialties Biochemistry
Biophysics
Date 2018 Jan 13
PMID 29325758
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

MicroRNA-186-5p (miR-186-5p) is upregulated and exhibits as a crucial oncogene in various human tumors. However, the functions and underlying mechanisms of this microRNA on colorectal cancer remain largely unknown. Here, we report that miR-186-5p share a lower expression in colorectal cancer cell lines (HT116, H29, SW620 and LoVo) than in normal colonic epithelial cell line NCM460. MiR-186-5p overexpression inhibits proliferation, metastasis and epithelial-to-mesenchymal transition (EMT) of colorectal cancer cell line LoVo. Zinc Finger E-Box Binding Homeobox 1 (ZEB1), an EMT related marker, is predicted as a target of miR-186-5p. Luciferase reporter assay, qRT-PCR and western blot analysis showed that miR-186-5p directly targeted the 3'-untranslated regions (3'UTR) of ZEB1 messenger RNA. Further functional experiments indicated that overexpression of miR-186-5p suppress the proliferation and metastasis ability of LoVo, which was consistent with the inhibitory effects by knockdown of ZEB1. Additionally, overexpression of ZEB1 could significantly reverse the miR-186-5p mimics initiated suppression impact of proliferation, metastasis and EMT on LoVo. In summary, miRNA-186-5p affects the proliferation, metastasis and EMT process of colorectal cancer cell by inhibition of ZEB1. Hence, it may serve as a promising therapeutic target for colorectal cancer.

Citing Articles

Exosomal microRNA as a key regulator of PI3K/AKT pathways in human tumors.

Jasim S, Ahmed A, Kubaev A, Kyada A, Alshahrani M, Sharma S Med Oncol. 2024; 41(11):265.

PMID: 39400677 DOI: 10.1007/s12032-024-02529-9.


LncRNA ANRIL Promotes Glucose Metabolism and Proliferation of Colon Cancer in a High-Glucose Environment and is Associated with Worse Outcome in Diabetic Colon Cancer Patients.

Mosaad H, Shalaby S, Mahmoud N, Ahmed M, Fayed A, Ashour H Asian Pac J Cancer Prev. 2024; 25(4):1371-1381.

PMID: 38679999 PMC: 11162718. DOI: 10.31557/APJCP.2024.25.4.1371.


METTL3-mediated mA modification of lncRNA SNHG3 accelerates gastric cancer progression by modulating miR-186-5p/cyclinD2 axis.

Ji G, Wang X, Xi H Int J Immunopathol Pharmacol. 2023; 37:3946320231204694.

PMID: 37823387 PMC: 10571673. DOI: 10.1177/03946320231204694.


MicroRNAs and colorectal cancer: clinical potential and regulatory networks.

Osei G, Adu-Amankwaah J, Koomson S, Beletaa S, Asiamah E, Smith-Togobo C Mol Biol Rep. 2023; 50(11):9575-9585.

PMID: 37776413 DOI: 10.1007/s11033-023-08810-w.


Novel insights on perils and promises of miRNA in understanding colon cancer metastasis and progression.

Tariq L, Arafah A, Sehar N, Ali A, Khan A, Rasool I Med Oncol. 2023; 40(10):282.

PMID: 37639075 DOI: 10.1007/s12032-023-02099-2.